Formulation development supported by light scattering techniques

contributed by Malvern Panalytical | 09/11/2017

Researchers develop methods to test protein stability under a variety of conditions.

Researchers from Novozymes Biopharma and Malvern Instruments have been collaborating using light scattering techniques to demonstrate the short- and long-term stability of the novel recombinant human albumins Albucult and Recombumin.

These rAlbumins have been developed and optimised to deliver a safe, stable and regulatorycompliant product for therapeutic formulations.

The teams applied the resolving and detection capabilities of size exclusion chromatography light scattering (SEC-LS) and dynamic light scattering (DLS) offered by Malvern systems to monitor the stability of these Novozymes products.

The work is described in an article ‘Tools for evaluating the stability of human recombinant albumins used in human therapeutics’. See: www.malvern.com/formulationdevelopment

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.